Skip to main content
SpringerLink
Log in

Oxidative stress markers are not valuable markers in lean and early age of polycystic ovary syndrome patients

  • Electronic Contents
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Background: Early atherosclerosis and increased risk of cardiovascular diseases (CVD) have been reported in patients with polycystic ovary syndrome (PCOS). Oxidative stress is an accepted risk factor for the development of CVD. Aim: To evaluate the association between oxidative stress markers [ischemia-modified albumin (IMA), total antioxidant status (TAS), and total oxidant status (TOS) levels], carotid intima-media thickness (CIMT), endocrine and metabolic parameters in patients with PCOS. Materials, subjects, and methods: We studied 52 patients with PCOS and 36 age- and body mass index (BMI)-matched controls. The diagnosis of PCOS was made according to the Rotterdam criteria. Metabolic, hormonal parameter and IMA, TAS, TOS levels were measured. Results: No statistically significant difference was determined in relation to age, BMI and waist-hip ratio, IMA, TAS, and TOS levels between groups. Mean IMA level was higher in PCOS patients, however, statistical significant difference was not observed. Mean CIMT and homeostasis model assessment of insulin resistance levels were significantly higher in patients with PCOS than in control subjects. Conclusion: Our study has shown that although CIMT levels, showing CVD risk, were higher in PCOS patients, TAS and TOS oxidative stress markers were found to be similar between groups, IMA was higher in PCOS patients however the difference was not reach statistical significant. The present results suggest that CIMT increases before the state of ischemia and shows preischemic state of vasculature, while oxidative stress markers are considered to be indicators of ischemia and reperfusion injury in progressive vascular disease. Further studies are needed to show the association between oxidative stress markers, CVD and PCOS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev 2009, 13: CD003053.

    Google Scholar 

  2. Pasquali R, Gambineri A, Pagotto U. The impact of obesity on reproduction in women with polycystic ovary syndrome. BJOG 2006, 113: 1148–59.

    Article  PubMed  Google Scholar 

  3. Orio F Jr, Palomba S, Spinelli L, et al. The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study. J Clin Endocrinol Metab 2004, 89: 3696–701.

    Article  PubMed  Google Scholar 

  4. Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N. Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2001, 86: 2453–5.

    Article  PubMed  Google Scholar 

  5. Kelly C, Speirs A, Gould G, Petrie J, Lyall H, Connell J. Altered vascular function in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 2002, 87: 742–6.

    Article  PubMed  Google Scholar 

  6. Escobar-Morreale HF, Luque-Ramírez M, San Millán JL. The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome. Endocr Rev 2005, 26: 251–82.

    Article  PubMed  Google Scholar 

  7. Sabuncu T, Vural H, Harma M, Harma M. Oxidative stress in poycystic ovary syndrome and its contribution to the risk of cardiovascular disease. Clin Biochem 2001, 34: 407–13.

    Article  PubMed  Google Scholar 

  8. Legro RS. Polycystic ovary syndrome and cardiovascular disease: a premature association. Endocrinol Rev 2003, 24: 302–12.

    Article  Google Scholar 

  9. Betteridge DJ. What is the oxidative stress? Metabolism 2000, 49: 13–8.

    Article  Google Scholar 

  10. Giugliano D, Ceriello A, Paolisso G. Oxidative stres and diabetic vascular complications. Diabetes Care 1996, 19: 257–67.

    Article  PubMed  Google Scholar 

  11. Garibaldi S, Valentini S, Aragno I, Pronzato MA, Traverso N and Odetti P. Plasma protein oxidation and antioxidant defense during aging. Int J Vitam Nutr Res 2001, 7: 332–8.

    Article  Google Scholar 

  12. Bar-Or D, Lau E, Winkler JV. Anovel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia-a preliminary report. J Emerg Med 2000, 19: 311–5.

    Article  PubMed  Google Scholar 

  13. Sene M, Kazan N, Co kun O, Zengi O, Inan L, Yücel D. Oxidative and nitrosative stress in acute ischaemic stroke. Ann Clin Biochem 2007, 44: 43–7.

    Article  Google Scholar 

  14. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term healthy risks related to polycystic ovary syndrome. Fertil Steril 2003, 81: 19–25.

    Google Scholar 

  15. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961, 21: 1440–7.

    Article  PubMed  Google Scholar 

  16. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28: 412–9.

    Article  PubMed  Google Scholar 

  17. Erel O. A novel automated method to measure total antioxidant response against potent free radical reactions. Clin Biochem 37, 2004: 112–9.

    Article  PubMed  Google Scholar 

  18. Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem 2005, 38: 1103–11.

    Article  PubMed  Google Scholar 

  19. Loverro G, Lorusso F, Mei L, Depalo R, Cormio G, Selvaggi L. The plasma homocysteine levels are increased in polycystic ovary syndrome. Gynecol Obstet Invest 2002, 53: 157–62.

    Article  PubMed  Google Scholar 

  20. Schachter M, Raziel A, Friedler S, Strassburger D, Bern O, Ron-El R. Insulin resistance in patients with polycystic ovary syndrome is associated with elevated plasma homocysteine. Hum Reprod 2003, 18: 721–7.

    Article  PubMed  Google Scholar 

  21. Wijeyaratne CN, Nirantharakumar K, Balen AH, Barth JH, Sheriff R, Belchetz PE. Plasma homocysteine in polycystic ovary syndrome: does it correlate with insulin resistance and ethnicity? Clin Endocrinol (Oxf) 2004, 60: 560–7.

    Article  Google Scholar 

  22. Guzick DS, Talbott EO, Sutton-Tyrrell K, Herzog HC, Kuller LH, Wolfson SK Jr. Carotid atherosclerosis in women with polycystic ovary syndrome: initial results from a case control study. Am J Obstet Gynecol 1996, 174: 1224–32.

    Article  PubMed  Google Scholar 

  23. Talbott EO, Guzick DS, Sutton-Tyrrell K, et al. Evidence for the association between polycystic ovary syndrome and premature carotid atherosclerosis in middle aged women. Arterioscler Thromb Vasc Biol 2000, 20: 2414–21.

    Article  PubMed  Google Scholar 

  24. Lakhani K, Hardiman P, Seifalian A. Intima-media thickness of elastic and muscular arteries in young women with polycystic ovaries. Atherosclerosis 2004, 175: 353–9.

    Article  PubMed  Google Scholar 

  25. Meyer C, McGrath BP, Teede HJ. Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease. J Clin Endocrinol Metab 2005, 90: 5711–6.

    Article  PubMed  Google Scholar 

  26. Yilmaz M, Bukan N, Ayvaz G, Karakoç A, Törüner F, Cakir N, Arslan M. The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome. Hum Reprod 2005, 20: 3333–40.

    Article  PubMed  Google Scholar 

  27. Boulman N, Levy Y, Leiba R, et al. Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. J Clin Endocrinol Metab 2004, 89: 2160–5.

    Article  PubMed  Google Scholar 

  28. Pasceri V, Willerson JT, Yeh ETH. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000, 102: 2165–8.

    Article  PubMed  Google Scholar 

  29. Lagrand WK, Visser CA, Hermens WT, et al. C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? Circulation 1999, 100: 96–102.

    Article  PubMed  Google Scholar 

  30. Verit FF. High sensitive serum C-reactive protein and its relationship with other cardiovascular risk factors in normoinsulinemic polycystic ovary patients without metabolic syndrome. Arch Gynecol Obstet 2010, 281: 1009–14.

    Article  PubMed  Google Scholar 

  31. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998, 98: 731–3.

    Article  PubMed  Google Scholar 

  32. Fearon IM, Faux SP. Oxidative stress and cardiovascular disease: novel tools give (free) radical insight. J Mol Cell Cardiol 2009, 47: 372–81.

    Article  PubMed  Google Scholar 

  33. Fenkci V, Fenkci S, Yilmazer M, Serteser M. Decreased total antioxidant status and increased oxidative stress in women with polycystic ovary syndrome may contribute to the risk of cardiovascular disease. Fertil Steril 2003, 80: 123–7.

    Article  PubMed  Google Scholar 

  34. Verit FF, Erel O. Oxidative stress in nonobese women with polycystic ovary syndrome: correlations with endocrine and screening parameters. Gynecol Obstet Invest 2008, 65: 233–9.

    Article  PubMed  Google Scholar 

  35. Mohamadin AM, Habib FA, Elahi TF. Serum paraoxonase 1 activity and oxidant/antioxidant status in Saudi women with polycystic ovary syndrome. Pathophysiology 2010, 17: 189–96.

    Article  PubMed  Google Scholar 

  36. Mather KJ, Kwan F, Corenblum B. Hyperinsulinemia in polycystic ovary syndrome correlates with increased cardiovascular risk independent of obesity. Fertil Steril 2000, 73: 150–6.

    Article  PubMed  Google Scholar 

  37. Superko HR, Gadesam RR. Is it LDL particle size or number that correlates with risk for cardiovascular disease? Review. Curr Atheroscler Rep 2008, 10: 377–85.

    Article  PubMed  Google Scholar 

  38. Kim JS, Hwang HJ, Ko YG, et al. Ischemia-modified albumin: is it a reliable diagnostic and prognostic marker for myocardial ischemia in real clinical practice? Cardiology 2010, 116: 123–9.

    Article  PubMed  Google Scholar 

  39. Valle Gottlieb MG, da Cruz IB, Duarte MM, et al. Associations among metabolic syndrome, ischemia, inflammatory, oxidatives, and lipids biomarkers. J Clin Endocrinol Metab 2009, 95: 586–91.

    Article  Google Scholar 

  40. Duarte MM, Rocha JB, Moresco RN, et al. Association between ischemia-modified albumin, lipids and inflammation biomarkers in patients with hypercholesterolemia. Clin Biochem 2009, 42: 666–71.

    Article  PubMed  Google Scholar 

  41. Kaefer M, Piva SJ, De Carvalho JA, et al. Association between ischemia modified albumin, inflammation and hyperglycemia in type 2 diabetes mellitus. Clin Biochem 2009, 43: 450–4.

    Article  PubMed  Google Scholar 

  42. Dahiya K, Aggarwal K, Seth S, Singh V, Sharma TK. Type 2 diabetes mellitus without vascular complications and ischemia modified albumin. Clin Lab 2010, 56: 187–90.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Endocrinology and Metabolism, Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey

    E. Cakir MD, M. Ozbek, N. Colak, E. Cakal, M. Sayki, A. Gungunes & T. Delibasi

  2. Department of Obstetrics and Gynecology, Sami Ulus Maternity and Women’s Health Training and Research Hospital, Ankara, Turkey

    E. Ozkaya

  3. Division of Biochemistry, Karadeniz Technical University, Faculty of Medicine, Trabzon, Turkey

    Y. Aliyazicioglu & A. Mentese

Authors
  1. E. Cakir MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Ozbek
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. Ozkaya
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. N. Colak
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E. Cakal
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. Sayki
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A. Gungunes
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Y. Aliyazicioglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. A. Mentese
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. T. Delibasi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E. Cakir MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cakir, E., Ozbek, M., Ozkaya, E. et al. Oxidative stress markers are not valuable markers in lean and early age of polycystic ovary syndrome patients. J Endocrinol Invest 34, e178–e182 (2011). https://doi.org/10.3275/7352

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.3275/7352

Key-words

Search

Navigation